Tenax Therapeutics (TENX) Competitors $5.88 -0.10 (-1.59%) As of 02:26 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TENX vs. ZURA, SAVA, HLVX, COYA, CHRS, MGNX, CLYM, PLRX, ANIX, and ONCYShould you be buying Tenax Therapeutics stock or one of its competitors? The main competitors of Tenax Therapeutics include Zura Bio (ZURA), Cassava Sciences (SAVA), HilleVax (HLVX), Coya Therapeutics (COYA), Coherus Oncology (CHRS), MacroGenics (MGNX), Climb Bio (CLYM), Pliant Therapeutics (PLRX), Anixa Biosciences (ANIX), and Oncolytics Biotech (ONCY). These companies are all part of the "pharmaceutical products" industry. Tenax Therapeutics vs. Its Competitors Zura Bio Cassava Sciences HilleVax Coya Therapeutics Coherus Oncology MacroGenics Climb Bio Pliant Therapeutics Anixa Biosciences Oncolytics Biotech Zura Bio (NASDAQ:ZURA) and Tenax Therapeutics (NASDAQ:TENX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings. Do analysts rate ZURA or TENX? Zura Bio currently has a consensus target price of $14.33, suggesting a potential upside of 888.51%. Tenax Therapeutics has a consensus target price of $17.50, suggesting a potential upside of 197.37%. Given Zura Bio's higher probable upside, equities research analysts plainly believe Zura Bio is more favorable than Tenax Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zura Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Tenax Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Is ZURA or TENX more profitable? Tenax Therapeutics' return on equity of -31.51% beat Zura Bio's return on equity.Company Net Margins Return on Equity Return on Assets Zura BioN/A -42.84% -35.22% Tenax Therapeutics N/A -31.51%-30.35% Which has stronger earnings & valuation, ZURA or TENX? Tenax Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZura BioN/AN/A-$45.39M-$0.70-2.07Tenax TherapeuticsN/AN/A-$17.60M-$2.48-2.37 Does the media prefer ZURA or TENX? In the previous week, Zura Bio had 3 more articles in the media than Tenax Therapeutics. MarketBeat recorded 3 mentions for Zura Bio and 0 mentions for Tenax Therapeutics. Zura Bio's average media sentiment score of 0.78 beat Tenax Therapeutics' score of 0.00 indicating that Zura Bio is being referred to more favorably in the media. Company Overall Sentiment Zura Bio Positive Tenax Therapeutics Neutral Which has more risk & volatility, ZURA or TENX? Zura Bio has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500. Comparatively, Tenax Therapeutics has a beta of 1.46, meaning that its stock price is 46% more volatile than the S&P 500. Do institutionals and insiders have more ownership in ZURA or TENX? 61.1% of Zura Bio shares are held by institutional investors. Comparatively, 1.7% of Tenax Therapeutics shares are held by institutional investors. 14.2% of Zura Bio shares are held by company insiders. Comparatively, 3.1% of Tenax Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryZura Bio beats Tenax Therapeutics on 8 of the 13 factors compared between the two stocks. Get Tenax Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TENX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TENX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TENX vs. The Competition Export to ExcelMetricTenax TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$24.41M$2.98B$5.46B$9.67BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-2.3717.9229.9924.97Price / SalesN/A174.22375.5577.11Price / CashN/A41.8335.9458.58Price / Book0.227.308.165.68Net Income-$17.60M-$54.43M$3.25B$265.38M7 Day Performance-5.39%0.07%1.11%2.52%1 Month Performance2.17%5.24%2.80%1.86%1 Year Performance42.15%10.72%28.49%24.21% Tenax Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TENXTenax Therapeutics1.3084 of 5 stars$5.89-1.6%$17.50+197.4%+46.9%$24.41MN/A-2.379Upcoming EarningsZURAZura Bio3.7127 of 5 stars$1.46-2.7%$14.33+881.7%-58.1%$102.56MN/A-2.093Positive NewsUpcoming EarningsSAVACassava Sciences2.3563 of 5 stars$2.29+8.0%$54.50+2,279.9%-92.7%$102.41MN/A-1.5330News CoverageUpcoming EarningsHLVXHilleVax1.9246 of 5 stars$2.07+1.5%$2.00-3.4%+28.0%$102.29MN/A-0.9620News CoveragePositive NewsEarnings ReportUpcoming EarningsHigh Trading VolumeCOYACoya Therapeutics2.1575 of 5 stars$6.34+4.1%$16.50+160.3%+2.3%$101.86M$3.69M-5.936Upcoming EarningsCHRSCoherus Oncology3.7528 of 5 stars$0.87-1.1%$4.68+439.6%-28.7%$101.77M$266.96M-0.77330News CoverageMGNXMacroGenics4.2649 of 5 stars$1.64+3.8%$5.33+225.2%-52.4%$99.68M$152.43M-1.84430CLYMClimb Bio2.7183 of 5 stars$1.70+17.2%$9.00+429.4%N/A$97.99MN/A-0.719News CoveragePositive NewsUpcoming EarningsHigh Trading VolumePLRXPliant Therapeutics4.1377 of 5 stars$1.70+7.6%$13.31+683.1%-86.6%$96.99M$1.58M-0.4790News CoverageEarnings ReportAnalyst ForecastGap DownANIXAnixa Biosciences3.5017 of 5 stars$3.26+8.3%$9.00+176.1%-0.3%$96.96M$210K-8.585Analyst ForecastONCYOncolytics Biotech2.3146 of 5 stars$0.88-10.8%$4.33+390.7%-8.0%$96.43MN/A-3.0530News CoverageEarnings ReportGap Up Related Companies and Tools Related Companies Zura Bio Alternatives Cassava Sciences Alternatives HilleVax Alternatives Coya Therapeutics Alternatives Coherus Oncology Alternatives MacroGenics Alternatives Climb Bio Alternatives Pliant Therapeutics Alternatives Anixa Biosciences Alternatives Oncolytics Biotech Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TENX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredHow high will gold surge?Weiss Gold Veteran Makes Shocking New Call Weiss expert Sean Brodrick went out on a limb last year and decl...Weiss Ratings | SponsoredGold Hit $3,500. Here’s What’s Next…Gold just smashed through $3,500—and some experts believe that’s only the beginning. With big banks like Goldm...Reagan Gold Group | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenax Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenax Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
